EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data

Gian Paolo Fadini iD, Enrico Longato, Sara Poletto, Andrea Giaccari iD, Mariangela Ghiani, Marco Strazzabosco, Maddalena Trombetta iD, Giuseppe Penno iD, Angelo Avogaro iD, Anna Solini iD, Agostino Consoli, GLIMPLES study investigators and DARWIN‐Renal study investigators

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.70151 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Gian Paolo Fadini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Padova, Padua, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucosides, Benzhydryl Compounds, Glucagon-Like Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Diabetes Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Oral semaglutide and empagliflozin are commonly used for the management of type 2 diabetes (T2D), but head‐to‐head comparisons in real‐world settings are limited. We aimed to emulate the PIONEER‐2 trial using electronic health records to compare the effectiveness and persistence of oral semaglutide versus empagliflozin.

Methods

This was a retrospective multicentre study using electronic health records from Italian diabetes clinics. New users of oral semaglutide or empagliflozin were matched 1:2 and followed for up to 18 months. The primary outcome was HbA1c change; secondary outcomes included weight change and treatment persistence. Analyses used mixed models for repeated measures under both treatment policy and trial product estimands.

Results

After matching, we included new users of oral semaglutide ( n = 105) or empagliflozin ( n = 207). Mean age was 65 years, diabetes duration 10 years, baseline HbA1c 7.6%, BMI 29 kg/m 2 , and 94% were on metformin. Only 28.6% of new users of oral semaglutide reached the 14 mg dose and 31.4% of empagliflozin new users reached the 25 mg dose. HbA1c reduction was significantly greater with oral semaglutide than with empagliflozin (mean difference − 0.35%, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2GlucosidesBenzhydryl CompoundsGlucagon-Like PeptidesHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedGlycated HemoglobinAdministration, OralTreatment OutcomeBlood GlucoseWeight LossItalyGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

cohort studyempagliflozinreal‐world evidencesemaglutide

Substanzen

GlucosidesBenzhydryl CompoundsGlucagon-Like PeptidesHypoglycemic AgentsGlycated HemoglobinBlood GlucoseSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide 1Semaglutideempagliflozin

Autor:innen und Institutionen

  • Department of Medicine, University of Padova, Padua, Italy.
  • Laboratory of Experimental Diabetology, Veneto Institute of Molecular Medicine, Padua, Italy.
  • Department of Information Engineering, University of Padova, Padua, Italy.
  • Endocrine and Metabolic Center, Fondazione Policlinico Universitario A. Gemelli IRCCS and Università Cattolica del Sacro Cuore, Rome, Italy.
  • Diabetology Unit, Azienda Sanitaria Locale 8 Cagliari Quartu S. Elena, Cagliari, Italy.
  • Diabetology and Metabolic Diseases Unit, S. Bortolo Hospital, Vicenza, Italy.

ORCID-Profile: Gian Paolo Fadini, Andrea Giaccari, Maddalena Trombetta, Giuseppe Penno, Angelo Avogaro, Anna Solini

Förderung

  • Italian Diabetes Society

Zitieren

APA

Fadini, G. P., Longato, E., Poletto, S., Giaccari, A., Ghiani, M., Strazzabosco, M., Trombetta, M., Penno, G., Avogaro, A., Solini, A., Consoli, A., & GLIMPLES study investigators and DARWIN‐Renal study investigators (2025). Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70151

Vancouver

Fadini GP, Longato E, Poletto S, Giaccari A, Ghiani M, Strazzabosco M, et al. Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70151

BibTeX
@article{Fadini2025,
  author = {Fadini, Gian Paolo and Longato, Enrico and Poletto, Sara and Giaccari, Andrea and Ghiani, Mariangela and Strazzabosco, Marco and Trombetta, Maddalena and Penno, Giuseppe and Avogaro, Angelo and Solini, Anna and Consoli, Agostino and GLIMPLES study investigators and DARWIN‐Renal study investigators, GLIMPLES study investigators and DARWIN‐Renal study investigators},
  title = {Effectiveness of oral semaglutide versus empagliflozin for the management of type 2 diabetes. PIONEER ‐2 trial emulation with real‐world data},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.70151}
}
Kostenlos starten →